Bibliographic Info
Recommendation
Recommended in favor
Strong
Certainty of evidence
High
In areas with chloroquine-susceptible infections, adults and children with uncomplicated P. vivax, P. ovale, P. malariae or P. knowlesi malaria should be treated with either an ACT or chloroquine. In areas with chloroquine-resistant infections, adults and children with uncomplicated P. vivax, P. ovale, P. malariae or P. knowlesi malaria should be treated with an ACT.
Also Featured In
This recommendation also appears in the following guidelines:
Guidelines for the treatment of malaria
WHO guidelines for malaria, 16 February 2021.
WHO guidelines for malaria, 13 July 2021.
WHO guidelines for malaria, 18 February 2022.
WHO guidelines for malaria, 31 March 2022.
WHO guidelines for malaria, 3 June 2022.
WHO guidelines for malaria, 25 November 2022.
WHO guidelines for malaria, 16 October 2023.
WHO Guidelines for malaria, 14 March 2023